We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-8.77%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$152M
AUM Growth
-$18.7M
Cap. Flow
+$1.22M
Cap. Flow %
0.8%
Top 10 Hldgs %
86.83%
Holding
51
New
9
Increased
9
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$1.47M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$838K
3
ALBO
Albireo Pharma Inc
ALBO
+$808K
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$609K
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$587K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$3.35M
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$1.8M
3
AXGN icon
Axogen
AXGN
+$521K
4
CORT icon
Corcept Therapeutics
CORT
+$361K
5
QDEL icon
QuidelOrtho
QDEL
+$233K

Sector Composition

Rank Sector Weight
1 Healthcare 96.14%
2 Energy 2.62%
3 Industrials 0.37%
4 Consumer Staples 0.35%
5 Consumer Discretionary 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
26
Biogen
BIIB
$29.6B
$548K 0.36%
2,000
+1,000
+100% +$310K
YTEN
27
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$528K 0.35%
282
– –
BIOL
28
DELISTED
Biolase, Inc.
BIOL
$522K 0.34%
103
– –
PXD
29
DELISTED
Pioneer Natural Resource Co.
PXD
$515K 0.34%
3,000
– –
FOLD
30
DELISTED
Amicus Therapeutics
FOLD
$511K 0.34%
34,000
+24,000
+240% +$365K
TSRO
31
DELISTED
TESARO, Inc.
TSRO
$469K 0.31%
8,200
+3,000
+58% +$193K
DRNA
32
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$430K 0.28%
45,000
– –
SHPG
33
DELISTED
Shire pic
SHPG
$403K 0.27%
+2,700
New +$372K
ARNA
34
DELISTED
Arena Pharmaceuticals Inc
ARNA
$395K 0.26%
+10,000
New +$389K
XNCR icon
35
Xencor
XNCR
$1.4B
$369K 0.24%
12,300
– –
OMED
36
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$314K 0.21%
98,689
+70,000
+244% +$193K
MYGN icon
37
Myriad Genetics
MYGN
$557M
$296K 0.19%
+10,000
New +$338K
AVEO
38
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$290K 0.19%
+10,000
New +$293K
ABLX
39
DELISTED
Ablynx NV
ABLX
$273K 0.18%
+5,000
New +$248K
ICPT
40
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$265K 0.17%
4,300
– –
CLVS
41
DELISTED
Clovis Oncology, Inc.
CLVS
$264K 0.17%
5,000
– –
GNMX
42
DELISTED
Aevi Genomic Medicine Inc
GNMX
$257K 0.17%
128,000
– –
GNCA
43
DELISTED
Genocea Biosciences, Inc.
GNCA
$198K 0.13%
23,625
+18,750
+385% +$156K
QTNT
44
DELISTED
Quotient Limited Ordinary Shares
QTNT
$187K 0.12%
993
-500
-33% -$90.2K
SLDB icon
45
Solid Biosciences
SLDB
$838M
$150K 0.1%
+1,333
New +$450K
WKHS icon
46
Workhorse Group
WKHS
$30.6M
$132K 0.09%
17
– –
CYTK icon
47
Cytokinetics
CYTK
$10.8B
$72K 0.05%
10,000
– –
CELGZ
48
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$70K 0.05%
241,877
-50,000
-17% -$32.8K
ANTH
49
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-15,378
Closed -$23K
AAAP
50
DELISTED
Advanced Accelerator Applications S.A.
AAAP
– –
-22,000
Closed -$1.8M
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Birchview Capital held 51 positions worth $152M, down 11% from $171M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Birchview Capital's Q1 2018 filing shows 9 new, 9 increased, 8 reduced and 2 closed positions. Its largest new stake was Atara Biotherapeutics: 920 shares worth $897K. The largest sale was Celgene Corp, an estimated $3.35M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Industrials.

  • Birchview Capital's largest Q1 2018 buy was Atara Biotherapeutics: 920 shares worth $897K.
  • Birchview Capital added most to Array Biopharma Inc in Q1 2018, an estimated $1.47M increase.
  • Birchview Capital's biggest Q1 2018 reduction was Celgene Corp, cutting an estimated $3.35M.
  • Birchview Capital fully exited Advanced Accelerator Applications S.A. in Q1 2018, selling an estimated $1.8M.
  • Birchview Capital's ten largest holdings make up 87% of its $152M portfolio in Q1 2018.
  • Birchview Capital opened 9 new positions and closed 2 in Q1 2018.
  • Birchview Capital's portfolio value fell 11% quarter-over-quarter to $152M.

Based on Birchview Capital's 13F filing for Q1 2018, filed 7 May 2018.